Open Access<p>Optimal Management of Complicated Infections in the Pediatric Patient: The Role and Utility of Ceftazidime/Avibactam</p>
Author(s) -
Matteo Bassetti,
Maddalena Peghin,
Alessio Mesini,
Elio Castagnola
Publication year - 2020
Publication title -
infection and drug resistance
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 39
ISSN - 1178-6973
DOI - 10.2147/idr.s209264
Subject(s) - ceftazidime/avibactam , avibactam , ceftazidime , cephalosporin , medicine , antibiotics , antimicrobial , intensive care medicine , multiple drug resistance , population , gram negative bacterial infections , antibiotic resistance , broad spectrum , microbiology and biotechnology , biology , environmental health , chemistry , bacteria , pseudomonas aeruginosa , genetics , combinatorial chemistry
Antimicrobial resistance poses a substantial threat to global public health. The pursuit of new antibiotics has decreased and very few options have been investigated for the treatment of complicated multidrug-resistant Gram-negative (MDR-GN) infections in adult population and even less in pediatric patients. Ceftazidime-avibactam (CAZ-AVI) is novel cephalosporin/β-lactamase inhibitor (BL-BLI) combination with broad antibacterial spectrum. The aim of this review is to describe the current and future role CAZ-AVI in the pediatric population with suspected or confirmed MDR-GN infections.